C4 Therapeutics Unveils Pipeline Strategy Focused on Protein Degraders for Oncology and Inflammatory Diseases

Reuters01-20

C4 <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Unveils Pipeline <a href="https://laohu8.com/S/MSTR">Strategy</a> Focused on Protein Degraders for Oncology and Inflammatory Diseases

C4 Therapeutics Inc. outlined its progress in advancing targeted protein degradation (TPD) medicines, with a focus on clinical oncology and discovery programs in inflammation, neuroinflammation, and neurodegeneration $(INN)$ diseases. The company highlighted ongoing and upcoming clinical trials, including the Phase 2 MOMENTUM trial and a Phase 1b trial evaluating cemsidomide in multiple myeloma, as well as the development of CFT8919 for non-small cell lung cancer. Key milestones over the next several years include the completion of clinical trial enrollments, data readouts, initiation of Phase 3 studies, and submission of a New Drug Application (NDA) for cemsidomide. C4 Therapeutics also reported a cash runway expected to extend through the end of 2028. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. C4 Therapeutics Inc. published the original content used to generate this news brief on January 20, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2604190498?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-20 20:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2604190498","market":"us","top_or_hot":-1,"title":"C4 Therapeutics Unveils Pipeline Strategy Focused on Protein Degraders for Oncology and Inflammatory Diseases","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      C4 <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Unveils Pipeline <a href=\"https://laohu8.com/S/MSTR\">Strategy</a> Focused on Protein Degraders for Oncology and Inflammatory Diseases\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        C4 Therapeutics Inc. outlined its progress in advancing targeted protein degradation (TPD) medicines, with a focus on clinical oncology and discovery programs in inflammation, neuroinflammation, and neurodegeneration <a href=\"https://laohu8.com/S/INN\">$(INN)$</a> diseases. The company highlighted ongoing and upcoming clinical trials, including the Phase 2 MOMENTUM trial and a Phase 1b trial evaluating cemsidomide in multiple myeloma, as well as the development of CFT8919 for non-small cell lung cancer. Key milestones over the next several years include the completion of clinical trial enrollments, data readouts, initiation of Phase 3 studies, and submission of a New Drug Application (NDA) for cemsidomide. C4 Therapeutics also reported a cash runway expected to extend through the end of 2028. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. C4 Therapeutics Inc. published the original content used to generate this news brief on January 20, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>C4 Therapeutics Unveils Pipeline Strategy Focused on Protein Degraders for Oncology and Inflammatory Diseases</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nC4 Therapeutics Unveils Pipeline Strategy Focused on Protein Degraders for Oncology and Inflammatory Diseases\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-20 20:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      C4 <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Unveils Pipeline <a href=\"https://laohu8.com/S/MSTR\">Strategy</a> Focused on Protein Degraders for Oncology and Inflammatory Diseases\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        C4 Therapeutics Inc. outlined its progress in advancing targeted protein degradation (TPD) medicines, with a focus on clinical oncology and discovery programs in inflammation, neuroinflammation, and neurodegeneration <a href=\"https://laohu8.com/S/INN\">$(INN)$</a> diseases. The company highlighted ongoing and upcoming clinical trials, including the Phase 2 MOMENTUM trial and a Phase 1b trial evaluating cemsidomide in multiple myeloma, as well as the development of CFT8919 for non-small cell lung cancer. Key milestones over the next several years include the completion of clinical trial enrollments, data readouts, initiation of Phase 3 studies, and submission of a New Drug Application (NDA) for cemsidomide. C4 Therapeutics also reported a cash runway expected to extend through the end of 2028. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. C4 Therapeutics Inc. published the original content used to generate this news brief on January 20, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nNDL14qF1v:1","article_id":"2604190498","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2604190498","pubTimestamp":1768911178,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"C4 Therapeutics Inc. outlined its progress in advancing targeted protein degradation  medicines, with a focus on clinical oncology and discovery programs in inflammation, neuroinflammation, and neurodegeneration  diseases. The company highlighted ongoing and upcoming clinical trials, including the Phase 2 MOMENTUM trial and a Phase 1b trial evaluating cemsidomide in multiple myeloma, as well as the development of CFT8919 for non-small cell lung cancer. Key milestones over the next several years include the completion of clinical trial enrollments, data readouts, initiation of Phase 3 studies, and submission of a New Drug Application  for cemsidomide. C4 Therapeutics also reported a cash runway expected to extend through the end of 2028. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated conten","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CCCC":"C4 Therapeutics, Inc."},"translate_title":"C4 Therapeutics推出专注于肿瘤学和炎症性疾病蛋白质降解剂的管道战略","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CCCC":0.9},"content_text":"C4 Therapeutics Unveils Pipeline Strategy Focused on Protein Degraders for Oncology and Inflammatory Diseases\n    \n\n        C4 Therapeutics Inc. outlined its progress in advancing targeted protein degradation (TPD) medicines, with a focus on clinical oncology and discovery programs in inflammation, neuroinflammation, and neurodegeneration $(INN)$ diseases. The company highlighted ongoing and upcoming clinical trials, including the Phase 2 MOMENTUM trial and a Phase 1b trial evaluating cemsidomide in multiple myeloma, as well as the development of CFT8919 for non-small cell lung cancer. Key milestones over the next several years include the completion of clinical trial enrollments, data readouts, initiation of Phase 3 studies, and submission of a New Drug Application (NDA) for cemsidomide. C4 Therapeutics also reported a cash runway expected to extend through the end of 2028. You can access the full presentation through the link below.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. C4 Therapeutics Inc. published the original content used to generate this news brief on January 20, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2604190498","isCrawlerRequest":true}